First Venture publicerade den 21 november 2024 bolagets delårsrapport för det tredje kvartalet av 20...
Redeye comments on Enviro’s Q3 report, which reported positive earnings for a third consecutive quar...
Automations- och säkerhetsbolaget Kentima levererade ett starkt kvartal trots en svag marknad.
Redeye comments on Jumpgates Q3 results, which was in line with our forecasts regarding sales and ma...
Beyond Frames reported net sales that were 8% lower than Redeye's estimate.
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) meddelade den 20 november år 20...
Q3 weak but it's a small quarter for '24e Estimates for Pome divestment pushed to '25e from '24e Sal...
Redeye updates its view on Flexion Mobile following its Q3 2024 report, which was largely in line wi...
Största ägaren Symrise lägger ett bud om 350 kronor per aktie i syfte att förvärva hela bolaget.
Redeye comments on Ngenic’s announcement of a SEK34m rights issue of units consisting of shares and ...
Redeye comments on the outcome of Iconovo’s rights issue.
Luxbright (”Luxbright” eller ”Bolaget”) fortsätter att uppvisa starkt momentum med flera framgångar ...
Medical cannabis has been legal in Denmark under a pilot program since 2018 during a trial period th...
Redeye comments on Flexion Mobile's Q3 2024 report, which was better than expected in terms of margi...
Q3 EBIT -94m (ABGSCe SEK -19m) Minor estimate revisions, given Q3 small quarter Fågelås, Boarp, Dåll...
Redeye comments on Alligator's sale of two bispecific antibodies to Orion, which were being develope...
Redeye updates its fair value range following Friday’s Q3 report and after the outcome of the extra ...
Redeye comments on Lytix' Q3 report. The main event since our last update is the start of the NeoLIP...
FY'24 ARR guidance lowered to DKK 101m-106m on KYC delays.
Redeye provides a research update following the Q3 report recently published by Coegin Pharma.